Nanomedicine in diagnostics and therapy of cardiovascular diseases: Beyond atherosclerotic plaque imaging

Nanotechnology Reviews

Volumn 2, Issue 4, 2013, Pages 449-472

  Cicha, Iwona ^a   Lyer, Stefan ^a   Alexiou, Christoph ^a   Garlichs, Christoph D ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Atherosclerosis; Nanoparticles; Plaque imaging; Stent design; Vascular tissue engineering

Indexed keywords

CARDIOLOGY; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DISEASE CONTROL; DRUG DOSAGE; MEDICAL NANOTECHNOLOGY; NANOMAGNETICS; NANOPARTICLES; STENTS; TARGETED DRUG DELIVERY; TISSUE; TISSUE ENGINEERING; TRANSPLANTATION (SURGICAL);

ATHEROSCLEROSIS; ATHEROSCLEROTIC LESIONS; CARDIO-VASCULAR DISEASE; CLINICAL MANIFESTATION; MAGNETIC NANO-PARTICLES; PLAQUE IMAGING; STENT DESIGN; VASCULAR TISSUE ENGINEERING;

DISEASES;

EID: 84902258875     PISSN: 21919089     EISSN: 21919097     Source Type: Journal    
DOI: 10.1515/ntrev-2013-0009     Document Type: Review

References (106)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127, e6-e245.
2. Slevin M, Badimon L, Grau-Olivares M, Ramis M, Sendra J, Morrison M, Krupinski J. Combining nanotechnology with current biomedical knowledge for the vascular imaging and treatment of atherosclerosis. Mol. Biosyst. 2010, 6, 444-450.
3. Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat. Rev. Drug Discov. 2011, 10, 835-852.
4. Smith BR, Heverhagen J, Knopp M, Schmalbrock P, Shapiro J, Shiomi M, Moldovan NI, Ferrari M, Lee SC. Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI). Biomed. Microdevices 2007, 9, 719-727.
5. Korosoglou G, Weiss RG, Kedziorek DA, Walczak P, Gilson WD, Schar M, Sosnovik DE, Kraitchman DL, Boston RC, Bulte JW, Weissleder R, Stuber M. Noninvasive detection of macrophagerich atherosclerotic plaque in hyperlipidemic rabbits using " positive contrast " magnetic resonance imaging. J. Am. Coll. Cardiol. 2008, 52, 483-491.
6. Hahn MA, Singh AK, Sharma P, Brown SC, Moudgil BM. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal. Bioanal. Chem. 2011, 399, 3-27.
7. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 1999, 99, 2293-2352.
8. Korkusuz H, Ulbrich K, Bihrer V, Welzel K, Chernikov V, Knobloch T, Petersen S, Huebner F, Ackermann H, Gelperina S, Korkusuz Y, Kromen W, Hammerstingl R, Haupenthal J, Fiehler J, Zeuzem S, Kreuter J, Vogl TJ, Piiper A. Contrast enhancement of the brain by folate-conjugated gadolinium-diethylenetriaminepentaacetic acid-human serum albumin nanoparticles by magnetic resonance imaging. Mol. Imaging 2012, 11, 272-279.
9. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 2004, 126, 16316-16317.
10. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 2006, 6, 2220-2224.
11. Dellinger A, Olson J, Zhou Z, Link K, Vance S, Sandros MG, Yang J, Kepley CL. Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 2013, 15, 7.
12. Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weissleder R. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol. Imaging 2006, 5, 85-92.
13. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, Frederik PM, Daemen MJ, van Engelshoven JM. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003, 107, 2453-2458.
14. Schellenberger EA, Sosnovik D, Weissleder R, Josephson L. Magneto/optical annexin V, a multimodal protein. Bioconjug. Chem. 2004, 15, 1062-1067.
15. Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G, Reynolds F, Grazette L, Rosenzweig A, Weissleder R, Josephson L. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn. Reson. Med. 2005, 54, 718-724.
16. Harris TJ, von Maltzahn G, Derfus AM, Ruoslahti E, Bhatia SN. Proteolytic actuation of nanoparticle self-assembly. Angew. Chem. Int. Ed. Engl. 2006, 45, 3161-3165.
17. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, Libby P, Swirski FK, Weissleder R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008, 117, 379-387.
18. Wang T, Mancuso JJ, Sapozhnikova V, Dwelle J, Ma LL, Willsey B, Kazmi SM, Qiu J, Li X, Asmis R, Johnston KP, Feldman MD, Milner TE. Dual-wavelength multifrequency photothermal wave imaging combined with optical coherence tomography for macrophage and lipid detection in atherosclerotic plaques using gold nanoparticles. J. Biomed. Opt. 2012, 17, 036009.
19. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109, III27-32.
20. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 2005, 96, 327-336.
21. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114, 1504-1511.
22. McAteer MA, Schneider JE, Ali ZA, Warrick N, Bursill CA, von zur Muhlen C, Greaves DR, Neubauer S, Channon KM, Choudhury RP. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 77-83.
23. Reynolds PR, Larkman DJ, Haskard DO, Hajnal JV, Kennea NL, George AJ, Edwards AD. Detection of vascular expression of E-selectin in vivo with MR imaging. Radiology 2006, 241, 469-476.
24. Wang XF, Jin PP, Tong Z, Zhao YP, Ding QL, Wang DB, Zhao GM, Jing D, Wang HL, Ge HL. MR molecular imaging of thrombus: development and application of a Gd-based novel contrast agent targeting to P-selectin. Clin. Appl. Thromb. Hemost. 2010, 16, 177-183.
25. Jacobin-Valat MJ, Deramchia K, Mornet S, Hagemeyer CE, Bonetto S, Robert R, Biran M, Massot P, Miraux S, Sanchez S, Bouzier-Sore AK, Franconi JM, Duguet E, Clofent-Sanchez G. MRI of inducible P-selectin expression in human activated platelets involved in the early stages of atherosclerosis. NMR Biomed. 2011, 24, 413-424.
26. Oh J, Feldman MD, Kim J, Sanghi P, Do D, Mancuso JJ, Kemp N, Cilingiroglu M, Milner TE. Detection of macrophages in atherosclerotic tissue using magnetic nanoparticles and differential phase optical coherence tomography. J. Biomed. Opt. 2008, 13, 054006.
27. Morishige K, Kacher DF, Libby P, Josephson L, Ganz P, Weissleder R, Aikawa M. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation 2010, 122, 1707-1715.
28. Sigovan M, Kaye E, Lancelot E, Corot C, Provost N, Majd Z, Breisse M, Canet-Soulas E. Anti-inflammatory drug evaluation in ApoE-/-mice by ultrasmall superparamagnetic iron oxideenhanced magnetic resonance imaging. Invest. Radiol. 2012, 47, 546-552.
29. Hamzah J, Kotamraju VR, Seo JW, Agemy L, Fogal V, Mahakian LM, Peters D, Roth L, Gagnon MK, Ferrara KW, Ruoslahti E. Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA 2011, 108, 7154-7159.
30. Lipinski MJ, Frias JC, Amirbekian V, Briley-Saebo KC, Mani V, Samber D, Abbate A, Aguinaldo JG, Massey D, Fuster V, Vetrovec GW, Fayad ZA. Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc. Imaging 2009, 2, 637-647.
31. Tu C, Ng TS, Sohi HK, Palko HA, House A, Jacobs RE, Louie AY. Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques. Biomaterials 2011, 32, 7209-7216.
32. Chen W, Vucic E, Leupold E, Mulder WJ, Cormode DP, Briley-Saebo KC, Barazza A, Fisher EA, Dathe M, Fayad ZA. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol. Imaging 2008, 3, 233-242.
33. Wen S, Liu DF, Liu Z, Harris S, Yao YY, Ding Q, Nie F, Lu T, Chen HJ, An YL, Zang FC, Teng GJ. OxLDL-targeted iron oxide nanoparticles for in vivo MRI detection of perivascular carotid collar induced atherosclerotic lesions in ApoE-deficient mice. J. Lipid Res. 2012, 53, 829-838.
34. van Tilborg GA, Vucic E, Strijkers GJ, Cormode DP, Mani V, Skajaa T, Reutelingsperger CP, Fayad ZA, Mulder WJ, Nicolay K. Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. Bioconjug. Chem. 2010, 21, 1794-1803.
35. Burtea C, Ballet S, Laurent S, Rousseaux O, Dencausse A, Gonzalez W, Port M, Corot C, Vander Elst L, Muller RN. Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler. Thromb. Vasc. Biol. 2012, 32, e36-48.
36. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003, 108, 2270-2274.
37. Winter PM, Caruthers SD, Allen JS, Cai K, Williams TA, Lanza GM, Wickline SA. Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrintargeted nanoparticles. Magn. Reson. Med. 2010, 64, 369-376.
38. Liu Y, Pressly ED, Abendschein DR, Hawker CJ, Woodard GE, Woodard PK, Welch MJ. Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET. J. Nucl. Med. 2011, 52, 1956-1963.
39. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104, 1280-1285.
40. Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E. Targeting atherosclerosis by using modular, multifunctional micelles. Proc. Natl. Acad. Sci. US A 2009, 106, 9815-9819.
41. Makowski MR, Forbes SC, Blume U, Warley A, Jansen CH, Schuster A, Wiethoff AJ, Botnar RM. In vivo assessment of intraplaque and endothelial fibrin in ApoE(-/-) mice by molecular MRI. Atherosclerosis 2012, 222, 43-49.
42. Mulder WJ, Strijkers GJ, Griffioen AW, van Bloois L, Molema G, Storm G, Koning GA, Nicolay K. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug. Chem. 2004, 15, 799-806.
43. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W, Jr., Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108, 1664-1672.
44. Rogers WJ, Basu P. Factors regulating macrophage endocytosis of nanoparticles: implications for targeted magnetic resonance plaque imaging. Atherosclerosis 2005, 178, 67-73.
45. Motomura K, Ishitobi M, Komoike Y, Koyama H, Noguchi A, Sumino H, Kumatani Y, Inaji H, Horinouchi T, Nakanishi K. SPIO-enhanced magnetic resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography lymphography in patients with breast cancer. Ann. Surg. Oncol. 2011, 18, 3422-3429.
46. te Boekhorst BC, Bovens SM, Nederhoff MG, van de Kolk KW, Cramer MJ, van Oosterhout MF, Ten Hove M, Doevendans PA, Pasterkamp G, van Echteld CJ. Negative MR contrast caused by USPIO uptake in lymph nodes may lead to false positive observations with in vivo visualization of murine atherosclerotic plaque. Atherosclerosis 2010, 210, 122-129.
47. Uchida M, Kosuge H, Terashima M, Willits DA, Liepold LO, Young MJ, McConnell MV, Douglas T. Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano 2011, 5, 2493-2502.
48. Le Dall J, Ho-Tin-Noe B, Louedec L, Meilhac O, Roncal C, Carmeliet P, Germain S, Michel JB, Houard X. Immaturity of microvessels in haemorrhagic plaques is associated with proteolytic degradation of angiogenic factors. Cardiovasc. Res. 2010, 85, 184-193.
49. Somanath PR, Malinin NL, Byzova TV. Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 2009, 12, 177-185.
50. Yu X, Song SK, Chen J, Scott MJ, Fuhrhop RJ, Hall CS, Gaffney PJ, Wickline SA, Lanza GM. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn. Reson. Med. 2000, 44, 867-872.
51. Almer G, Saba-Lepek M, Haj-Yahya S, Rohde E, Strunk D, Frohlich E, Prassl R, Mangge H. Globular domain of adiponectin: promising target molecule for detection of atherosclerotic lesions. Biologics 2011, 5, 95-105.
52. Almer G, Wernig K, Saba-Lepek M, Haj-Yahya S, Rattenberger J, Wagner J, Gradauer K, Frascione D, Pabst G, Leitinger G, Mangge H, Zimmer A, Prassl R. Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques. Int. J. Nanomed. 2011, 6, 1279-1290.
53. Almer G, Frascione D, Pali-Scholl I, Vonach C, Lukschal A, Stremnitzer C, Diesner SC, Jensen-Jarolim E, Prassl R, Mangge H. Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomes. Mol. Pharm. 2013, 10, 175-186.
54. Hood ED, Greineder CF, Dodia C, Han J, Mesaros C, Shuvaev VV, Blair IA, Fisher AB, Muzykantov VR. Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo. J. Control. Release 2012, 163, 161-169.
55. Broz P, Ben-Haim N, Grzelakowski M, Marsch S, Meier W, Hunziker P. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin. J. Cardiovasc. Pharmacol. 2008, 51, 246-252.
56. McCarthy JR, Korngold E, Weissleder R, Jaffer FA. A lightactivated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small 2010, 6, 2041-2049.
57. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, Zhang H, Wickline SA, Lanza GM. Endothelial alpha(v)beta3 integrintargeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2103-2109.
58. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc. Imaging 2008, 1, 624-634.
59. Luderer F, Lobler M, Rohm HW, Gocke C, Kunna K, Kock K, Kroemer HK, Weitschies W, Schmitz KP, Sternberg K. Biodegradable sirolimus-loaded poly(lactide) nanoparticles as drug delivery system for the prevention of in-stent restenosis in coronary stent application. J. Biomater. Appl. 2011, 25, 851-875.
60. Reddy MK, Vasir JK, Sahoo SK, Jain TK, Yallapu MM, Labhasetwar V. Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Circ. Cardiovasc. Interv. 2008, 1, 209-216.
61. Cyrus T, Zhang H, Allen JS, Williams TA, Hu G, Caruthers SD, Wickline SA, Lanza GM. Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 820-826.
62. Chan JM, Zhang L, Tong R, Ghosh D, Gao W, Liao G, Yuet KP, Gray D, Rhee JW, Cheng J, Golomb G, Libby P, Langer R, Farokhzad OC. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc. Natl. Acad. Sci. USA 2010, 107, 2213-2218.
63. Li JM, Newburger PE, Gounis MJ, Dargon P, Zhang X, Messina LM. Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model. Gene Ther. 2010, 17, 1279-1287.
64. Joner M, Morimoto K, Kasukawa H, Steigerwald K, Merl S, Nakazawa G, John MC, Finn AV, Acampado E, Kolodgie FD, Gold HK, Virmani R. Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1960-1966.
65. Korin N, Kanapathipillai M, Matthews BD, Crescente M, Brill A, Mammoto T, Ghosh K, Jurek S, Bencherif SA, Bhatta D, Coskun AU, Feldman CL, Wagner DD, Ingber DE. Shearactivated nanotherapeutics for drug targeting to obstructed blood vessels. Science 2012, 337, 738-742.
66. Shuvaev VV, Han J, Yu KJ, Huang S, Hawkins BJ, Madesh M, Nakada M, Muzykantov VR. PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J. 2011, 25, 348-357.
67. Ikuta K, Mori T, Yamamoto T, Niidome T, Shimokawa H, Katayama Y. Development of polymeric drug delivery system for recognizing vascular endothelial dysfunction. Bioorg. Med. Chem. 2008, 16, 2811-2818.
68. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 2006, 48, 2584-2591.
69. Blich M, Zeidan-Shwiri T, Petcherski S, Osherov A, Hammerman H. Incidence, predictors and outcome of drug-eluting stent thrombosis in real-world practice. J. Invasive Cardiol. 2010, 22, 461-464.
70. Marnane M, Merwick A, Sheehan OC, Hannon N, Foran P, Grant T, Dolan E, Moroney J, Murphy S, O ' Rourke K, O ' Malley K, O ' Donohoe M, McDonnell C, Noone I, Barry M, Crowe M, Kavanagh E, O ' Connell M, Kelly PJ. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann. Neurol. 2012, 71, 709-718.
71. Zhang WL, Xiao Y, Liu JP, Wu ZM, Gu X, Xu YM, Lu H. Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. Int. J. Pharm. 2011, 419, 314-321.
72. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 2054-2061.
73. Zweers ML, Engbers GH, Grijpma DW, Feijen J. Release of anti-restenosis drugs from poly(ethylene oxide)-poly(DL-lacticco-glycolic acid) nanoparticles. J. Control. Release 2006, 114, 317-324.
74. Danielyan K, Ding BS, Gottstein C, Cines DB, Muzykantov VR. Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema. J. Pharmacol. Exp. Ther. 2007, 321, 947-952.
75. Ta HT, Prabhu S, Leitner E, Jia F, von Elverfeldt D, Jackson KE, Heidt T, Nair AK, Pearce H, von Zur Muhlen C, Wang X, Peter K, Hagemeyer CE. Enzymatic single-chain antibody tagging: a universal approach to targeted molecular imaging and cell homing in cardiovascular disease. Circ. Res. 2011, 109, 365-373.
76. Klinkert P, Post PN, Breslau PJ, van Bockel JH. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur. J. Vasc. Endovasc. Surg. 2004, 27, 357-362.
77. Gabbieri D, Dohmen PM, Koch C, Lembcke A, Rutsch W, Konertz W. Aortocoronary endothelial cell-seeded polytetrafluoroethylene graft: 9-year patency. Ann. Thorac. Surg. 2007, 83, 1166-1168.
78. Meinhart JG, Deutsch M, Fischlein T, Howanietz N, Froschl A, Zilla P. Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts. Ann. Thorac. Surg. 2001, 71, S327-331.
79. L ' Heureux N, Paquet S, Labbe R, Germain L, Auger FA. A completely biological tissue-engineered human blood vessel. FASEB J. 1998, 12, 47-56.
80. Ito A, Ino K, Hayashida M, Kobayashi T, Matsunuma H, Kagami H, Ueda M, Honda H. Novel methodology for fabrication of tissue-engineered tubular constructs using magnetite nanoparticles and magnetic force. Tissue Eng. 2005, 11, 1553-1561.
81. Perea H, Aigner J, Hopfner U, Wintermantel E. Direct magnetic tubular cell seeding: a novel approach for vascular tissue engineering. Cells Tissues Organs 2006, 183, 156-165.
82. Perea H, Aigner J, Heverhagen JT, Hopfner U, Wintermantel E. Vascular tissue engineering with magnetic nanoparticles: seeing deeper. J. Tissue Eng. Regen. Med. 2007, 1, 318-321.
83. Gonzalez-Molina J, Riegler J, Southern P, Ortega D, Frangos CC, Angelopoulos Y, Husain S, Lythgoe MF, Pankhurst QA, Day RM. Rapid magnetic cell delivery for large tubular bioengineered constructs. J. R. Soc. Interface. 2012, 9, 3008-3016.
84. Akiyama H, Ito A, Sato M, Kawabe Y, Kamihira M. Construction of cardiac tissue rings using a magnetic tissue fabrication technique. Int. J. Mol. Sci. 2010, 11, 2910-2920.
85. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation 1999, 99, 44-52.
86. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J. Am. Coll. Cardiol. 2004, 44, 1373-1385.
87. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O ' Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 2003, 349, 1315-1323.
88. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O ' Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. J. Am. Med. Assoc. 2005, 294, 1215-1223.
89. Nakano K, Egashira K, Masuda S, Funakoshi K, Zhao G, Kimura S, Matoba T, Sueishi K, Endo Y, Kawashima Y, Hara K, Tsujimoto H, Tominaga R, Sunagawa K. Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC Cardiovasc. Interv. 2009, 2, 277-283.
90. Johnson B, Toland B, Chokshi R, Mochalin V, Koutzaki S, Polyak B. Magnetically responsive paclitaxel-loaded biodegradable nanoparticles for treatment of vascular disease: preparation, characterization and in vitro evaluation of anti-proliferative potential. Curr. Drug Deliv. 2010, 7, 263-273.
91. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 2006, 48, 193-202.
92. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J. Am. Med. Assoc. 2005, 293, 2126-2130.
93. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006, 113, 2803-2809.
94. Masuda S, Nakano K, Funakoshi K, Zhao G, Meng W, Kimura S, Matoba T, Miyagawa M, Iwata E, Sunagawa K, Egashira K. Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. J. Atheroscler. Thromb. 2011, 18, 1043-1053.
95. Tsukie N, Nakano K, Matoba T, Masuda S, Iwata E, Miyagawa M, Zhao G, Meng W, Kishimoto J, Sunagawa K, Egashira K. Pitavastatin-incorporated nanoparticleeluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model. J. Atheroscler. Thromb. 2013, 20, 32-45.
96. De Scheerder I, Verbeken E, Van Humbeeck J. Metallic surface modification. Semin. Interv. Cardiol. 1998, 3, 139-144.
97. Tepe G, Wendel HP, Khorchidi S, Schmehl J, Wiskirchen J, Pusich B, Claussen CD, Duda SH. Thrombogenicity of various endovascular stent types: an in vitro evaluation. J. Vasc. Interv. Radiol. 2002, 13, 1029-1035.
98. Dibra A, Kastrati A, Mehilli J, Pache J, von Oepen R, Dirschinger J, Schomig A. Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized double-blind controlled trial. Catheter Cardiovasc. Interv. 2005, 65, 374-380.
99. Lu J, Khang D, Webster TJ. Greater endothelial cell responses on submicron and nanometer rough titanium surfaces. J. Biomed. Mater. Res. A 2010, 94, 1042-1049.
100. Palmaz JC, Benson A, Sprague EA. Influence of surface topography on endothelialization of intravascular metallic material. J. Vasc. Interv. Radiol. 1999, 10, 439-444.
101. Khang D, Lu J, Yao C, Haberstroh KM, Webster TJ. The role of nanometer and sub-micron surface features on vascular and bone cell adhesion on titanium. Biomaterials 2008, 29, 970-983.
102. Biela SA, Su Y, Spatz JP, Kemkemer R. Different sensitivity of human endothelial cells, smooth muscle cells and fibroblasts to topography in the nano-micro range. Acta Biomater. 2009, 5, 2460-2466.
103. Sprague EA, Tio F, Ahmed SH, Granada JF, Bailey SR. Impact of parallel micro-engineered stent grooves on endothelial cell migration, proliferation, and function: an in vivo correlation study of the healing response in the coronary swine model. Circ. Cardiovasc. Interv. 2012, 5, 499-507.
104. Sosnovik DE, Caravan P. Molecular MRI of the Cardiovascular System in the Post-NSF Era. Curr. Cardiovasc. Imaging Rep. 2013, 6, 61-68.
105. Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, Rigothier C, Billiouw JM, Campioni P, Ferreiros J, Devos D, Alison D, Glowacki F, Boffa JJ, Marti-Bonmati L. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur. Radiol. 2013, 23, 1250-1259.
106. Singh N, Jenkins GJ, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 2010, 1, 5358-5373.